Vicore Pharma (VICO) investor relations material

Financial and Operational Highlights

• Market cap is $370 million with $110–111 million in cash as of early 2026.

• Supported by a broad base of institutional and specialist investors in the US and Europe.

• Operations span Stockholm, Cambridge (MA), and Copenhagen.

Company Vision and Background

• Aims to transform patient outcomes by targeting the AT2 receptor to halt and reverse disease pathology.

• Focused on developing disease-modifying drugs for respiratory and fibrotic diseases.

• Publicly listed on Nasdaq Stockholm under ticker VICO.

Clinical and Research Updates

• Buloxibutid is an oral, selective AT2 receptor agonist in a global Phase 2b ASPIRE trial for IPF, with enrollment completed ahead of schedule.

• The ASPIRE trial is randomized, double-blind, placebo-controlled, with 378 patients across 14 countries; topline data expected mid-2027.

• A pre-planned futility analysis will occur after 27% of patients complete the study, with results expected in Q4 2026.

• Buloxibutid has Orphan Drug and Fast Track designation from the FDA.

• Japanese rights for buloxibutid were licensed to Nippon Shinyaku in 2024.